The U.S. diabetes monitoring, treatment, and drug delivery market was valued at $48 billion in 2024 and is projected to grow at a CAGR of 7.3%, reaching $79 billion by 2031.
This report covers key market segments, including:
- Blood Glucose Meters, Blood Glucose Test Strips, Lancets
- Continuous Glucose Monitoring (CGM) & Flash Glucose Monitoring (FGM)
- Insulin & GLP-1 Receptor Agonists (e.g., Ozempic®)
- Insulin Pens, Insulin Syringes, and Insulin Pumps
Key Market Segment Insights
The largest and fastest-growing segment in 2024 was the insulin and GLP-1 receptor agonist market, which accounted for the majority of total market value. The growth of GLP-1 therapies is driven by:
- Rising prevalence of type 2 diabetes and obesity
- Increased demand for innovative treatment solutions
- Advancements in therapies that address both diabetes and obesity
- Market Data Highlights
The report includes:
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Market Drivers & Limiters
- Market Forecasts Until 2031 and Historical Data from 2021
- Competitive Analysis & Market Shares
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- U.S. Diabetes Market Trends
- Smart Reusable Insulin Pens: The demand for smart insulin pens is increasing due to their ability to track doses, calculate insulin requirements, and provide reminders. These devices enhance diabetes management and offer greater convenience despite higher pricing.
- Technological Advancements: Continuous improvements in CGM, insulin delivery systems, and digital health solutions are expected to drive the market forward.
Market Share Insights
Top Competitors in the U.S. Diabetes Market (2024):
1 Novo Nordisk
- Market leader in insulin and second in insulin pens.
- Top position in ultra-long-acting & ultra-rapid-acting insulin.
- Only competitor in the rapid-acting insulin market.
- GLP-1 portfolio includes Ozempic®, Rybelsus®, and Xultophy®.
2 Eli Lilly
- Second-largest competitor in the insulin market.
- Leader in premixed insulin, ultra-rapid-acting insulin, and human insulin.
- GLP-1 portfolio includes Trulicity®, Mounjaro®, and Zepbound®.
3 Dexcom
- Dominates the continuous glucose monitoring (CGM) market.
- Strong sales from G6® (FDA approval in 2018) and G7 (FDA approval in 2023).
Market Segmentation Summary
This report suite includes all relevant market data, but individual MedCore reports are available for specific segments.
Blood Glucose Meter Market
- Segmented Into: Personal & Professional
Blood Glucose Test Strip Market
- Segmented Into: Personal & Professional
Lancet Market
- Segmented Into: Personal & Professional
Continuous Glucose Monitoring (CGM) Market
- Segmented Into: Personal & Professional
Flash Glucose Monitoring (FGM) Market
- Segmented Into: Readers & Sensors
- Insulin and GLP-1 Market
- Insulin Types: Long-Acting, Ultra-Long-Acting, Rapid-Acting, Ultra-Rapid-Acting, Premixed, Human
- GLP-1 Segments:
Diabetes Care: GLP-1 Injection, GLP-1 Oral
Obesity Care: GLP-1 Injection
Insulin Pen Market
- Segmented Into: Reusable Pens & Pen Needles
Insulin Syringe Market
- Segmented Into: Conventional & Safety Syringes
Insulin Pump Market
- Segmented Into: Durable, Patch, and Simple Pumps
- Global Research Scope
Report Attributes and Details:
- Region: United States
- Base Year: 2024
- Forecast Period: 2025-2031
- Historical Data: 2021-2023
Quantitative Coverage:
- Market Size, Market Shares, Market Forecasts, Growth Rates
- Units Sold, Average Selling Prices
Qualitative Coverage:
- COVID-19 Impact
- Market Trends & Limiters
- Competitive Analysis & SWOT for Leading Competitors
- Mergers & Acquisitions
- Company Profiles & Product Portfolios
- FDA Recalls & Disruptive Technologies
- Disease Overviews
Data Sources:
- Industry Leader Interviews
- Government & Regulatory Data
- Hospital & Private Sector Data
- Import & Export Records
- Research Internal Database
Table of Contents
- List of Figures
- List of Charts
- Executive Summary
- U.S. Diabetes Monitoring, Treatment and Drug Delivery Market Overview
- Competitive Analysis
- Emerging Markets and Technologies
- Market Developments
- Market Trends
- Market Segmentation
- Key Report Updates
- Version History
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- Home Aide Diagnostics
- ACON Laboratories
- iHealth Labs
- AgaMatrix
- Infopia
- Allison Medical
- Insulet
- ApexBio
- Intuity Medical
- Arcadia Group
- i-SENS
- ARKRAY
- LifeScan
- Ascensia
- Livongo Health
- AstraZeneca
- McKesson
- B. Braun
- Medlin
- BD
- Medtronic
- Bionime
- Nova Biomedical
- Biosense Medical Devices
- Novo Nordisk
- Boehringer Ingelheim
- Oak Tree Health
- Companion Medical
- Omnis Health
- CanAm
- One Drop
- CVS
- Owen Mumford
- DarioHealth
- Perrigo
- Eli Lilly
- Pharma Supply
- Excel International
- Philosys
- Fifty 50 Medical
- Platinum Equity
- ForaCare
- Playtex
- Genesis Health Technologies
- Prodigy
- Gluco Perfect
- Retractable Technologies
- Hikma Pharmaceuticals
- Roche
- Sanofi
- Terumo
- SD Biosensor
- Trivia Health
- Senseonics
- U.S. Diagnostics
- Simple Diagnostics
- UltiMed
- Smart Meter
- Unilife Medical Solutions
- Smiths Medical
- Valeritas
- Specialty Medical Supplies
- Vertex Diagnostics
- STAT Medical Devices
- Viatris
- Tandem
- Walmart
- Teva Pharmaceuticals
- Ypsomed
- Telcare